Sep 14, 2020   SOURCE: PR NewsWire

Global Primary Sclerosing Cholangitis Market Spotlight Report 2020: Gilead Sciences has Two Completed Trials and Two Ongoing Trials in PSC

DUBLIN, Sept. 14, 2020 /PRNewswire/ -- The "Market Spotlight: Primary Sclerosing Cholangitis" report has been added to ResearchAndMarkets.com's offering.

https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

Primary sclerosing cholangitis (PSC) is a progressive, rare, and chronic cholestatic liver disorder that is characterized by thickening, inflammation, and fibrosis of the bile ducts. Both intra- and extra-hepatic bile ducts are affected. This generally leads to cholestasis, liver cirrhosis, and eventually liver failure.

Key Takeaways

    --  The publisher estimates that in 2019, there were 241,800 prevalent cases
        of primary sclerosing cholangitis (PSC) worldwide among adults aged 30
        years and over, and forecasts that number to increase to 277,300
        prevalent cases by 2028. - - The majority of industry-sponsored drugs in
        active clinical development for PSC are in Phase II, with only two drugs
        in Phase III. Therapies in the pipeline for PSC focus on a wide variety
        of targets. The majority of pipeline drugs in development are
        administered via the oral route, with the remainder being tested in
        intravenous and subcutaneous formulations.
    --  The only high-impact upcoming event for drugs in the PSC space is
        topline Phase II trial results for HTD1801. The overall likelihood of
        approval of a Phase I autoimmune/immunology-other asset is 21.8%, and
        the average probability a drug advances from Phase III is 70.2%. Drugs,
        on average, take 9.8 years from Phase I to approval, compared to 9.0
        years in the overall autoimmune/immunology space.
    --  The distribution of clinical trials across Phase I-IV indicates that the
        majority of trials for PSC have been in the early and midphases of
        development, with 80% of trials in Phase I-II, and only 20% in Phase
        III.
    --  The US leads in terms of the number of PSC clinical trials globally,
        while the UK leads the major European markets.
    --  Gilead Sciences has two completed trials and two ongoing trials in PSC.
    --  Gilead Sciences has conducted two Phase II trials for PSC, as well as a
        single trial in Phase I and in Phase III.

Key Topics Covered:

Overview

Key Takeaways

Disease Background

    --  Subtypes

Treatment

Epidemiology

Pipeline Drugs

Recent Events and Analyst Opinion

    --  Seladelpar for PSC (November 25, 2019)

Key Upcoming Events

Probability of Success

Clinical Trial Landscape

    --  Sponsors by status
    --  Sponsors by phase

Bibliography

Appendix

For more information about this report visit https://www.researchandmarkets.com/r/7j8cf4

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-primary-sclerosing-cholangitis-market-spotlight-report-2020-gilead-sciences-has-two-completed-trials-and-two-ongoing-trials-in-psc-301128480.html

SOURCE Research and Markets